Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.56 |
| ▸ | CDK2 | P24941 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | CDK7 | P50613 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345514 | 1.00 | IGF1R (0.60) | IGF1REGFRKCNH2CDK2CYP3A4 | |
| SCHEMBL2346628 | 0.92 | EGFR (0.67) | IGF1REGFRKCNH2CDK2CYP3A4 | |
| SCHEMBL3310189 | 0.92 | EGFR (0.67) | IGF1REGFRKCNH2CDK2CYP3A4 | |
| SCHEMBL3349646 | 0.92 | EGFR (0.67) | IGF1REGFRKCNH2CDK2CYP3A4 | |
| SCHEMBL2350163 | 0.92 | IGF1R (0.65) | IGF1REGFRKCNH2CDK2 | |
| SCHEMBL2348737 | 0.90 | IGF1R (0.62) | IGF1REGFRKCNH2CDK2CYP3A4 | |
| SCHEMBL3313052 | 0.89 | IGF1R (0.67) | IGF1REGFRKCNH2CDK2CYP3A4 | |
| SCHEMBL3345531 | 0.85 | IGF1R (0.66) | IGF1REGFRKCNH2CDK2 | |
| SCHEMBL2354282 | 0.85 | IGF1R (0.74) | IGF1REGFRKCNH2CDK2CYP3A4 | |
| SCHEMBL2342901 | 0.85 | IGF1R (0.65) | IGF1REGFRKCNH2CDK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| EP-2536728-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | IGF1R 1391/4885EGFR 1117/4885KCNH2 2973/4885 |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | IGF1R 1560/4885EGFR 753/4885KCNH2 2443/4885 |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | IGF1R 1560/4885EGFR 753/4885KCNH2 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.